Investseekers shares fresh $NVO and $LLY script numbers pointing to ongoing pressure on Novo Nordisk's obesity treatments, with a note on Wegovy.
Recap by typeshit. Post by Investseekers on X.
The MFDS approval rests on SURPASS-CVOT, where Mounjaro matched Trulicity on heart events in 13,000+ patients but did not prove superior.
Inside Retail Asia looks at skincare and aesthetic treatments brands are building for facial volume loss after rapid weight loss.
The actor told an interviewer people can take Ozempic carefree, while stressing that nothing replaces actually working out.
CFO MV Narasimham says the company still expects to ship 6 to 7 million pens across 10 approved markets between November and March, with Canada taking most of them.
Bikman says the added glucagon receptor push raises energy use and liver fat burning, and points to 24.2% weight loss on 12 mg in phase 2.
Bauer argues weight loss was never about willpower and describes how GLP-1 drugs can quiet cravings. Full episode on the podcast.
Loading…